BRAF and non-small cell lung carcinoma: The National Comprehensive Cancer Network (NCCN) NSCLC panel currently recommends BRAF mutation testing for of all patients with metastatic non-squamous NSCLC and suggests the combination targeted therapy of dabrafenib plus trametinib as a preferred first-line therapy for BRAFV600E-mutant NSCLC patients [164].